

WEST Search History

DATE: Saturday, March 24, 2007

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L79	L75 and streptococcus	9
<input type="checkbox"/>	L78	L75 and (rumen)adj(bacteria)	0
<input type="checkbox"/>	L77	L76 and rumen	0
<input type="checkbox"/>	L76	L75 and bacteria	51
<input type="checkbox"/>	L75	(stimulate)adj(adhesion)	127
<input type="checkbox"/>	L74	(stimulate)adj(adhesion)adj(antigen)	0
<input type="checkbox"/>	L73	L72 and (thioglycollate)	3
<input type="checkbox"/>	L72	(lactobacillus)adj(spp)	459
<input type="checkbox"/>	L71	L65 and (adherence)adj(antigen?)	1
<input type="checkbox"/>	L70	L65 and (stimulate)same(adherence)adj(antigens)	0
<input type="checkbox"/>	L69	L65 and (stimulate)same(adherence)adj(antigen)	0
<input type="checkbox"/>	L68	L67 and thioglycollate	1
<input type="checkbox"/>	L67	L65 and (brain)adj(heart)adj(infusion)	27
<input type="checkbox"/>	L66	L65 and (standard)adj(medium)	1
<input type="checkbox"/>	L65	(s)adj(bovis)	285
	<i>DB=USPT; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L64	4748018.pn.	1
<input type="checkbox"/>	L63	5080895.pn.	1
<input type="checkbox"/>	L62	6287555.pn.	1
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L61	L57 and (brain)adj(heart)adj(infusion)	8
	<i>DB=EPAB; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L60	DE-69930288-T2.did.	0
	<i>DB=DWPI; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L59	200030661	2
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L58	L57 and (adhesion)	3
<input type="checkbox"/>	L57	(streptococcus)adj(bovis)same(culture)	48
<input type="checkbox"/>	L56	L55 and IgY	11
<input type="checkbox"/>	L55	(530/389.5).ccls.	240
<input type="checkbox"/>	L54	L52 and (lactic)adj(acid)same(bacteria)	4

<input type="checkbox"/>	L53	L52 and (lactic)adj(acid)adj(inducing)adj(bacteria)	0
<input type="checkbox"/>	L52	L51 and IgY	690
<input type="checkbox"/>	L51	(435/69.1).ccls.	26661
<input type="checkbox"/>	L50	L49 and IgY	4
<input type="checkbox"/>	L49	(424/169.1).ccls.	61
<input type="checkbox"/>	L48	L46 and (s)adj(bovis)	0
<input type="checkbox"/>	L47	L46 and (lactic)adj(acid)adj(producing)adj(bacteria)	0
<input type="checkbox"/>	L46	L45 and IgY	19
<input type="checkbox"/>	L45	(424/164.1).ccls.	298
<input type="checkbox"/>	L44	L41 and (s)adj(bovis)	1
<input type="checkbox"/>	L43	L41 and (lactic)adj(acid)adj(producing)adj(bacteria)	0
<input type="checkbox"/>	L42	L41 and (lactic)adj(acid)adj(producing)adj(immunogen)	1
<input type="checkbox"/>	L41	L40 and IgY	50
<input type="checkbox"/>	L40	(424/130.1).ccls.	2082
<input type="checkbox"/>	L39	(acidosis)same(streptococcus)adj(bovis)	15
<input type="checkbox"/>	L38	(acidosis)same(strep)adj(bovis)	0
<input type="checkbox"/>	L37	(IgY)same(strep)adj(bovis)	0
<input type="checkbox"/>	L36	(IgY)same(anti-adherence)	0
<input type="checkbox"/>	L35	(IgY)same(dietary)adj(supplement)	0
<i>DB=USPT; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L34	4550019.pn.	1
<input type="checkbox"/>	L33	3947836.pn.	1
<input type="checkbox"/>	L32	3794732.pn.	1
<input type="checkbox"/>	L31	5919451.pn.	1
<input type="checkbox"/>	L30	5753268.pn.	1
<input type="checkbox"/>	L29	5585098.pn.	1
<input type="checkbox"/>	L28	5367054.pn.	1
<input type="checkbox"/>	L27	5196193.pn.	1
<input type="checkbox"/>	L26	4748018.pn.	1
<input type="checkbox"/>	L25	4550019.pn.	1
<input type="checkbox"/>	L24	5080895.pn.	1
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L23	L22 and IgY	4
<input type="checkbox"/>	L22	(streptococcus)adj(bovis)	648
<input type="checkbox"/>	L21	(streptocossu)adj(bovis)	0
<input type="checkbox"/>	L20	L19 and bovis	10
<input type="checkbox"/>	L19	L18 and streptococcus	116
<input type="checkbox"/>	L18	L16 and antibod?	717

<input type="checkbox"/>	L17	L16 and IgY	18
<input type="checkbox"/>	L16	(feed)adj(additive)	8937
<input type="checkbox"/>	L15	(feed)adj(additive)same(IgY)	1
<input type="checkbox"/>	L14	(feed)adj(additive)same(IgY)same(acidosis)	0
<input type="checkbox"/>	L13	L12 and IgY	1
<input type="checkbox"/>	L12	(lactic)adj(acid)same(streptococcus)same(acidosis)	16
<input type="checkbox"/>	L11	L10 and IgY	5
<input type="checkbox"/>	L10	(lactic)adj(acid)same(microorganism)	3282
<input type="checkbox"/>	L9	(mitteness)adj(bradley)adj(M)	2
<input type="checkbox"/>	L8	(nash)adj(peter)	21
<input type="checkbox"/>	L7	(adherence)adj(inhibitor)same(IgY)	1
<input type="checkbox"/>	L6	L5 and (SB)adj(antigen)	1
<input type="checkbox"/>	L5	L4 and bovis	57
<input type="checkbox"/>	L4	L3 and (Streptococcus)	789
<input type="checkbox"/>	L3	(IgY)	4810
<input type="checkbox"/>	L2	(IgY)same(streptococcus)adj(bovis)	0
<i>DB=USPT; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L1	5585098.pn.	1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSSPTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	4	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	5	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	7	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	9	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	12	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	13	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	14	JAN 29	PHAR reloaded with new search and display fields
NEWS	15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	19	FEB 26	MEDLINE reloaded with enhancements
NEWS	20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	25	MAR 16	CASREACT coverage extended
NEWS	26	MAR 20	MARPAT now updated daily
NEWS	27	MAR 22	LWPI reloaded
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:01:19 ON 24 MAR 2007

=> file medline embase biosis scisearch caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 13:01:34 ON 24 MAR 2007

FILE 'EMBASE' ENTERED AT 13:01:34 ON 24 MAR 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:01:34 ON 24 MAR 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 13:01:34 ON 24 MAR 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 13:01:34 ON 24 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s acidosis bacteria
L1 1 ACIDOSIS BACTERIA

=> d l1 chib abs

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
1979:101428 Document No. 90:101428 Relationship of rumen gram-negative
bacteria and free endotoxin to lactic acidosis in cattle. Nagaraja, T.
G.; Bartley, E. E.; Fina, L. R.; Anthony, H. D. (Dep. Anim. Sci. Ind.,
Kansas State Univ., Manhattan, KS, USA). Journal of Animal Science
(Savoy, IL, United States), 47(6), 1329-37 (English) 1978. CODEN: JANSAG.
ISSN: 0021-8812.

AB Feeding grain to animals not adapted to grain resulted in a marked
increase in the concentration of free endotoxin in the rumen. Endotoxin
concentration
increased 15-18-fold within 12 h after lactic acidosis was induced through
grain engorgement. The increase was accompanied by a shift from
predominantly gram-neg. to gram-pos. bacteria. Data from in vitro ferms.
showed that the increase in free endotoxin concentration was not accompanied
by a
decrease in the number of gram-neg. bacteria. The absorption of endotoxin
from the rumen was not apparent by the actinomycin D assay procedure
because no difference was observed in mice lethality of plasma from control
and post-engorgement samples. However, the granulocytosis that
accompanied acidosis was suggestive of systemic action of rumen bacterial
endotoxin.

=> s streptococcus bovis
L2 4259 STREPTOCOCCUS BOVIS

=> s l2 and tryptase soy broth
L3 0 L2 AND TRYPTASE SOY BROTH

=> s l2 and growth medium
L4 43 L2 AND GROWTH MEDIUM

=> s l4 and adherins
L5 0 L4 AND ADHERINS

=> s l4 and adhesion molecule
L6 0 L4 AND ADHESION MOLECULE

=> s l4 and tryptase soy broth
L7 0 L4 AND TRYPTASE SOY BROTH

=> dup remove l4
PROCESSING COMPLETED FOR L4
L8 18 DUP REMOVE L4 (25 DUPLICATES REMOVED)

=> d l8 1-18 cbib abs

L8 ANSWER 1 OF 18 MEDLINE on STN DUPLICATE 1
2006546004. PubMed ID: 16971591. In vitro bacterial growth and in vivo ruminal microbiota populations associated with bloat in steers grazing wheat forage. Min B R; Pinchak W E; Anderson R C; Hume M E. (Texas Agricultural Experiment Station, P.O. Box 1658, Vernon, Texas 76385, USA.) Journal of animal science, (2006 Oct) Vol. 84, No. 10, pp. 2873-82. Journal code: 8003002. E-ISSN: 1525-3163. Pub. country: United States. Language: English.

AB The role of ruminal bacteria in the frothy bloat complex common to cattle grazing winter wheat has not been previously determined. Two experiments, one in vitro and another in vivo, were designed to elucidate the effects of fresh wheat forage on bacterial growth, biofilm complexes, rumen fermentation end products, rumen bacterial diversity, and bloat potential. In Exp. 1, 6 strains of ruminal bacteria (*Streptococcus bovis* strain 26, *Prevotella ruminicola* strain 23, *Eubacterium ruminantium* B1C23, *Ruminococcus albus* SY3, *Fibrobacter succinogenes* ssp. S85, and *Ruminococcus flavefaciens* C94) were used in vitro to determine the effect of soluble plant protein from winter wheat forage on specific bacterial growth rate, biofilm complexes, VFA, and ruminal H₂ and CH₄ in mono or coculture with *Methanobrevibacter smithii*. The specific growth rate in plant protein medium containing soluble plant protein (3.27% nitrogen) was measured during a 24-h incubation at 39 degrees C in Hungate tubes under a CO₂ gas phase. A monoculture of *M. smithii* was grown similarly, except under H₂:CO₂ (1:1), in a basal methanogen growth medium supplemented likewise with soluble plant protein. In Exp. 2, 6 ruminally cannulated steers grazing wheat forage were used to evaluate the influence of bloat on the production of biofilm complexes, ruminal microbial biodiversity patterns, and ruminal fluid protein fractions. In Exp. 1, cultures of *R. albus* (P < 0.01) and *R. flavefaciens* (P < 0.05) produced the most H₂ among strains and resulted in greater (P < 0.01) CH₄ production when cocultured with *M. smithii* than other coculture combinations. Cultures of *S. bovis* and *E. ruminantium* + *M. smithii* produced the most biofilm mass among strains. In Exp. 2, when diets changed from bermudagrass hay to wheat forage, biofilm production increased (P < 0.01). Biofilm production, concentrations of whole ruminal content (P < 0.01), and cheesecloth filtrate protein fractions (P < 0.05) in the ruminal fluid were greater on d 50 for bloated than for nonbloated steers when grazing wheat forage. The molecular analysis of the 16S rDNA showed that 2 different ruminal microbiota populations developed between bloated and nonbloated animals grazing wheat forage. Bloat in cattle grazing wheat pastures may be caused by increased production of biofilm, resulting from a diet-influenced switch in the rumen bacterial population.

L8 ANSWER 2 OF 18 MEDLINE on STN DUPLICATE 2
2003159175. PubMed ID: 12676687. Identification of equine cecal bacteria producing amines in an in vitro model of carbohydrate overload. Bailey S R; Baillon M-L; Rycroft A N; Harris P A; Elliott J. (Department of Veterinary Basic Sciences, Royal Veterinary College, London, United Kingdom.. jelliott@rvc.ac.uk) . Applied and environmental microbiology, (2003 Apr) Vol. 69, No. 4, pp. 2087-93. Journal code: 7605801. ISSN: 0099-2240. Pub. country: United States. Language: English.

AB Acute laminitis has been associated with the overgrowth of gram-positive

bacteria within the equine hindgut, causing the release of factor(s) leading to ischemia-reperfusion of the digits. The products of fermentation which trigger acute laminitis are, as yet, unknown; however, vasoactive amines are possible candidates. The objectives of this study were to use an in vitro model of carbohydrate overload to study the change in populations of cecal streptococci and lactobacilli and to establish whether certain species of these bacteria were capable of producing vasoactive amines from amino acids. Cecal contents from 10 horses were divided into aliquots and incubated anaerobically with either corn starch or inulin (fructan; both at 1 g/100 ml). Samples were taken at 6-h intervals over a 24-h period for enumeration of streptococci, lactobacilli, and gram-negative anaerobes by a dilution method onto standard selective growth media. The effects of the antibiotic virginiamycin (1 mg/100 ml) and calcium hydrogen phosphate (CaHPO₄; 0.3 g/100 ml) were also examined. Fermentation of excess carbohydrate was associated with increases in numbers of streptococci and lactobacilli (2- to 3.5-log unit increases; inhibited by virginiamycin) but numbers of gram-negative anaerobes were not significantly affected. A screening agar technique followed by 16S rRNA gene sequence analysis enabled the identification of 26 different bacterial strains capable of producing one or more vasoactive amines. These included members of the species *Streptococcus bovis* and five different *Lactobacillus* spp. These data suggest that certain bacteria, whose overgrowth is associated with carbohydrate fermentation, are capable of producing vasoactive amines which may play a role in the pathogenesis of acute laminitis.

L8 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

2002:841804 Document No. 138:234693 Bacteriology of the Labrador dog gut: a cultural and genotypic approach. Greetham, H. L.; Giffard, C.; Hutson, R. A.; Collins, M. D.; Gibson, G. R. (Food Microbial Sciences Unit, School of Food Biosciences, The University of Reading, Reading, UK). Journal of Applied Microbiology, 93(4), 640-646 (English) 2002. CODEN: JAMIFK. ISSN: 1364-5072. Publisher: Blackwell Science Ltd..

AB To carry out an extensive study of the microflora composition of the Labrador dog gut. Faecal specimens from four Labradors were collected and plated onto growth media designed to recover total anaerobes, bacteroides, bifidobacteria, lactobacilli, clostridia, Gram-pos. cocci, total aerobes and coliforms. Morphol. different isolates were collected from all agars inoculated with faeces from one canine individual (repeated four times). A total of 157 out of 171 isolates were identified using 16S rRNA gene sequencing. Sequence anal. showed that agar selectivity was poor, especially when bacteroides and Gram-pos. cocci were the targets. Bifidobacteria were not detected in any of the samples analyzed, indicating their presence at low or negligible levels. The gene sequences of many of the isolates (n = 45, representing 29% of the total) did not correlate with known species in the Ribosomal Database Project and EMBL databases, suggesting the presence of novel gut diversity. Traditional culture methods fail to reflect the bacterial diversity present in Labrador dog faeces. This study has shown the value of mol.-based methodologies for determining bacterial profiles in the Labrador dog gut microbiota, but has also exposed the limitations of purportedly selective agars.

L8 ANSWER 4 OF 18 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN

2002:328874 The Genuine Article (R) Number: 538AT. Influence of ammonia concentration on N-15-ammonia incorporation and de novo amino acid synthesis by the non-cellulolytic ruminal bacteria, *Prevotella bryantii* B(1)4, *Selenomonas ruminantium* HD4 and *Streptococcus bovis* ES1. Atasoglu C (Reprint); Wallace R J. Canakkale Onsekiz Mart Univ, Fac Agr, Dept Anim Sci, TR-17100 Canakkale, Turkey (Reprint); Rowett Res Inst, Aberdeen AB21 9SB, Scotland. TURKISH JOURNAL OF VETERINARY & ANIMAL SCIENCES (2002) Vol. 26, No. 2, pp. 389-395. ISSN: 1300-0128. Publisher: SCIENTIFIC TECHNICAL RESEARCH COUNCIL TURKEY, PO BOX

605 YENISEHIR, 06445 ANKARA, TURKEY. Language: English.

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The influence of ammonia concentration on N-15-ammonia incorporation and de novo synthesis of amino acids by three predominant non-cellulolytic species of ruminal bacteria, *Prevotella bryantii* B(1)4, *Selenomonas ruminantium* HD4 and *Streptococcus bovis* ES1, was investigated. The medium contained pancreatic casein hydrolysate (comprising mainly peptides with some amino acids) at a concentration of 1 g/litre and additions of graded concentrations of (NH₄Cl)-N-15. When the initial concentration of ammonia increased from 0.045 to 0.436 g N/L in the growth medium, the proportion of cellular nitrogen and amino acid nitrogen derived from ammonia by *P. bryantii* and *S. ruminantium* increased (ranging from 0.33 to 0.84 for cellular-nitrogen and from 0.23 to 0.67 for amino acid-nitrogen) ($P < 0.001$). but *S. bovis* incorporated a fixed proportion of ammonia and peptides in all media except for the lowest ammonia containing medium ($P > 0.05$). Glutamate and aspartate were the most highly labelled amino acids with N-15, whereas N-15 enrichment in proline was lower than that in other amino acids in all species, followed by phenylalanine in *P. bryantii*, lysine in *S. ruminantium* and phenylalanine, valine and lysine in *S. bovis*. indicating preferential incorporation of these amino acids from pancreatic casein hydrolysate. The results of the present study, thus, suggest that the concentration of ammonia has an important effect on de novo synthesis of bacterial cellular-nitrogen and amino acids in the non-cellulolytic ruminal bacteria and this effect depends on bacterial species.

L8 ANSWER 5 OF 18 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on
STN DUPLICATE 3

2002:470552 The Genuine Article (R) Number: 556TV. Characterization of superoxide dismutase in the rumen bacterium *Streptococcus bovis*. Holovska K; Lenartova V (Reprint); Holovska K; Javorsky P. Univ Vet Med, Komenskeho 73, Kosice 04181, Slovakia (Reprint); Univ Vet Med, Kosice 04181, Slovakia; Slovak Acad Sci, Inst Anim Physiol, Kosice, Slovakia. VETERINARNI MEDICINA (FEB-MAR 2002) Vol. 47, No. 2-3, pp. 38-44. ISSN: 0375-8427. Publisher: INST AGRICULTURAL FOOD INFORMATION, SLEZSKA 7, PRAGUE 120 56, CZECH REPUBLIC. Language: English.

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Superoxide dismutase (SOD) isoenzymes of the rumen bacterium *Streptococcus bovis* 4/1 were studied. Native PAGE showed a single band of Mn-SOD, unaffected by 10 mM cyanide or 5 mM hydrogen peroxide under both aerobic and anaerobic growth conditions. When the metals were removed from the growth medium by Chelex 100, the addition of manganese increased enzymatic activity, while addition of iron inhibited SOD activity. Changes in Mn-SOD and glutathione peroxidase (GSHPx) activities evoked by paraquat and increased values of TBARS indicated that these enzymes were not able to sufficiently prevent oxidative stress at given paraquat concentrations.

L8 ANSWER 6 OF 18 MEDLINE on STN DUPLICATE 4

2000005612. PubMed ID: 10537220. Physiological characterization of *Streptococcus bovis* mutants that can resist 2-deoxyglucose-induced lysis. Bond D R; Tsai B M; Russell J B. (Section of Microbiology, Cornell University and Agricultural Research Service, US Department of Agriculture, Ithaca, NY 14853, USA.) Microbiology (Reading, England), (1999 Oct) Vol. 145 (Pt 10), pp. 2977-85. Journal code: 9430468. ISSN: 1350-0872. Pub. country: ENGLAND: United Kingdom. Language: English.

AB *Streptococcus bovis* JB1 does not normally lyse, but stationary phase lysis can be induced by including 2-deoxyglucose (2DG) in the growth medium. Isolates deficient in glucose/2DG phosphotransferase activity (PTS-) also lysed when 2DG was present (Lys+) and this result indicated that 2DG phosphorylation via the PTS was not an obligate requirement for 2DG-induced lysis. Cells and cell walls from 2DG-grown cultures lysed faster when proteinase K was added, but glucose-grown cultures and cell walls were not affected. A lipoteichoic

acid (LTA) extract (aqueous phase from hot phenol treatment) from glucose-grown cells inhibited the lysis of 2DG-grown cultures, but a similar extract prepared from 2DG-grown cells was without effect. Thin-layer chromatography and differential staining indicated that wild-type and Lys⁺ PTS⁻ cells incorporated 2DG into LTA, but lysis-resistant cultures (Lys⁻ PTS⁺ and Lys⁻ PTS⁻) did not. LTA from lysis-resistant (Lys⁻ PTS⁺ and Lys⁻ PTS⁻) cells grown with glucose and 2DG also prevented 2DG-dependent lysis of the wild-type. LTA could not inhibit degradation of cell walls isolated from 2DG-grown cultures, but LTA inhibited the lysis of *Micrococcus lysodeikticus* (*Micrococcus luteus*) cells that were exposed to supernatants from 2DG-grown *S. bovis* cultures. Group D streptococci (including *S. bovis*) normally have an alpha-1,2 linked glucose disaccharide (kojibiose) in their LTA, but kojibiose cannot be synthesized from 2DG. This observation suggested that the kojibiose moiety of LTA was involved in autolysin inactivation. Wild-type *S. bovis* had ATP- as well as PEP-dependent mechanisms of 2DG phosphorylation and one lysis-resistant phenotype (Lys⁻ PTS⁻) had reduced levels of both activities. However, the Lys⁻ PTS⁺ phenotype was still able to phosphorylate 2DG via ATP and PEP and this result indicated that some other step of 2DG incorporation into LTA was being inhibited. Based on these results, growth in the presence of 2DG appears to prevent synthesis of normal LTA, which is involved in the regulation of autolytic enzymes.

L8 ANSWER 7 OF 18 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN

1999:343318 The Genuine Article (R) Number: 192TJ. Alternative schemes of butyrate production in *Butyrivibrio fibrisolvens* and their relationship to acetate utilization, lactate production, and phylogeny. Diez-Gonzalez F; Bond D R; Jennings E; Russell J B (Reprint). Cornell Univ, Wing Hall, Ithaca, NY 14853 USA (Reprint); Cornell Univ, Ithaca, NY 14853 USA; ARS, USDA, Ithaca, NY 14853 USA. ARCHIVES OF MICROBIOLOGY (APR 1999) Vol. 171, No. 5, pp. 324-330. ISSN: 0302-8933. Publisher: SPRINGER-VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010 USA. Language: English.

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB *Butyrivibrio fibrisolvens* strains D1 and A38 produced little lactate, but strain 49 converted as much as 75% of its glucose to lactate. Strain 49 had tenfold more lactate dehydrogenase activity than strains D1 or A38, this activity was stimulated by fructose 1,6-bisphosphate, and had a pH optimum of 6.25. A role for fructose 1,6-bisphosphate or pH regulation of lactate production in strain 39 was, however, contradicted by the observations that very low concentrations (< 0.2 mM) of fructose 1,6-bisphosphate gave maximal activity, and continuous cultures did not produce additional lactate when the pH was decreased. The lactate production of strain 49 was clearly inhibited by the presence of acetate in the growth medium. When strain 49 was supplemented with as little as 5 mM acetate, lactate production decreased dramatically, and most of the glucose was converted to butyrate. Strain 49 did not possess butyrate kinase activity, but it had a butyryl-CoA/acetate CoA transferase that converted butyryl-CoA directly to butyrate, using acetate as an acceptor. The transferase had a low affinity for acetate (K_m of 5 mM), and this characteristic explained the acetate stimulation of growth and butyrate formation. Strains D1 and A38 had butyrate kinase but not butyryl-CoA/acetate CoA transferase, and it appeared that this difference could explain the lack of acetate stimulation and lactate production. Based on these results, it is unlikely that *B. fibrisolvens* would ever contribute significantly to the pool of ruminal lactate. Since relatives of strain 49 (strains Nor37, PI-7, VV1, and OB156, based on 16S rRNA sequence analysis) all had the same method of butyrate production, it appeared that butyryl-CoA/acetate CoA transferase might be a phylogenetic characteristic. We obtained a culture of strain B835 (NCDO 2398) that produced large amounts of lactate and had butyryl-CoA/acetate CoA transferase activity, but this strain had previously been grouped with strains A38 and DI based on 16S rRNA sequence analysis. Our strain B835 had a 16S rRNA sequence unique from the one currently deposited in GenBank, and had high sequence similarity with strains 39 and Nor37 rather

than with strains A38 or D1.

L8 ANSWER 8 OF 18 MEDLINE on STN DUPLICATE 5
95373990. PubMed ID: 7646013. Cellodextrin efflux by the cellulolytic ruminal bacterium *Fibrobacter succinogenes* and its potential role in the growth of nonadherent bacteria. Wells J E; Russell J B; Shi Y; Weimer P J. (Section of Microbiology, Cornell University, Ithaca, New York 14853, USA.) *Applied and environmental microbiology*, (1995 May) Vol. 61, No. 5, pp. 1757-62. Journal code: 7605801. ISSN: 0099-2240. Pub. country: United States. Language: English.

AB When glucose or cellobiose was provided as an energy source for *Fibrobacter succinogenes*, there was a transient accumulation (as much as 0.4 mM hexose equivalent) of cellobiose or cellotriose, respectively, in the growth medium. Nongrowing cell suspensions converted cellobiose to cellotriose and longer-chain cellodextrins, and in this case the total cellodextrin concentration was as much as 20 mM (hexose equivalent). Because cell extracts of glucose- or cellobiose-grown cells cleaved cellobiose and cellotriose by phosphate-dependent reactions and glucose 1-phosphate was an end product, it appeared that cellodextrins were being produced by a reversible phosphorylase reaction. This conclusion was supported by the observation that the ratio of cellodextrins to cellodextrins with one greater hexose [$n/(n + 1)$] was approximately 4, a value similar to the equilibrium constant (K_{eq}) of cellobiose phosphorylase (J. K. Alexander, J. Bacteriol. 81:903-910, 1961). When *F. succinogenes* was grown in a cellobiose-limited chemostat, cellobiose and cellotriose could both be detected, and the ratio of cellotriose to cellobiose was approximately 1 to 4. On the basis of these results, cellodextrin production is an equilibrium (mass action) function and not just an artifact of energy-rich cultural conditions. Cellodextrins could not be detected in low-dilution-rate, cellulose-limited continuous cultures, but these cultures had a large number of nonadherent cells. Because the nonadherent cells had a large reserve of polysaccharide and were observed at all stages of cell division, it appeared that they were utilizing cellodextrins as an energy source for growth. (ABSTRACT TRUNCATED AT 250 WORDS)

L8 ANSWER 9 OF 18 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN 1995:444011 Document No.: PREV199598458311. A defined medium for rumen bacteria and identification of strains impaired in de novo biosynthesis of certain amino acids. Nili, N.; Brooker, J. D. [Reprint author]. Dep. Anim. Sci., Waite Agric. Res. Inst., Univ. Adelaide, Glen Osmond, SA 5064, Australia. *Letters in Applied Microbiology*, (1995) Vol. 21, No. 2, pp. 69-74.

CODEN: LAMIE7. ISSN: 0266-8254. Language: English.
AB A completely defined growth medium has been developed to determine the nitrogen requirements for several species of ruminal bacteria, and has revealed two strains which are impaired in de novo biosynthesis of certain amino acids. Using NH₄Cl as a sole nitrogen source, the medium supported growth of *Butyrivibrio*, *Selenomonas*, *Prevotella* and *Streptococcus* species. One strain of *B. fibrisolvens* (E14) and one strain of *P. ruminicola* (GA33) did not grow in the presence of NH₄Cl until the medium was supplemented with amino acids or peptides. For *B. fibrisolvens* strain E 14, methionine was identified as the specific growth-limiting amino acid although methionine alone did not support growth in the absence of NH₄Cl. For *P. ruminicola* strain GA33, any individual amino acid other than methionine or cysteine could supplement the medium and support growth. Enzyme assays confirmed a lack of NADH and NADPH-dependent glutamate dehydrogenase (GDH) activities in this strain.

L8 ANSWER 10 OF 18 MEDLINE on STN DUPLICATE 6
94304158. PubMed ID: 8031077. Influence of *Yucca shidigera* extract on ruminal ammonia concentrations and ruminal microorganisms. Wallace R J; Arthaud L; Newbold C J. (Rowett Research Institute, Bucksburn, Aberdeen, United Kingdom.) *Applied and environmental microbiology*, (1994 Jun) Vol.

60, No. 6, pp. 1762-7. Journal code: 7605801. ISSN: 0099-2240. Pub. country: United States. Language: English.

- AB An extract of the desert plant *Yucca shidigera* was assessed for its possible benefit in ruminal fermentation. The extract bound ammonia in aqueous solution when concentrations of ammonia were low (up to 0.4 mM) and when the extract was added at a high concentration to the sample (20%, vol/vol). The apparent ammonia-binding capability was retained after autoclaving and was decreased slightly following dialysis. Acid-precipitated extract was inactive. No evidence of substantial ammonia binding was found at higher ammonia concentrations (up to 30 mM). When *Y. shidigera* extract (1%, vol/vol) was added to strained rumen fluid in vitro, a small (6%) but significant ($P < 0.05$) decrease in ammonia concentration occurred, apparently because of decreased proteolysis. Inclusion of *Y. shidigera* extract (1%, vol/vol) in the growth medium of the rumen bacterium *Streptococcus bovis* ES1 extended its lag phase, while growth of *Butyrivibrio fibrisolvens* SH13 was abolished. The growth of *Prevotella* (*Bacteroides*) *ruminicola* B(1)4 was stimulated, and that of *Selenomonas ruminantium* Z108 was unaffected. Protozoal activity, as measured by the breakdown of 14C-leucine-labelled *S. ruminantium* in rumen fluid incubated in vitro, was abolished by the addition of 1% extract. The antimicrobial activities were unaffected by precipitating tannins with polyvinylpyrrolidone, but a butanol extract, containing the saponin fraction, retained its antibacterial and antiprotozoal effects. Saponins from other sources were less effective against protozoa than *Y. shidigera* saponins. *Y. shidigera* extract, therefore, appears unlikely to influence ammonia concentration in the rumen directly, but its saponins have antimicrobial properties, particularly in suppressing ciliate protozoa, which may prove beneficial to ruminal fermentation and may lead indirectly to lower ruminal ammonia concentrations.

L8 ANSWER 11 OF 18 MEDLINE on STN DUPLICATE 7
94143602. PubMed ID: 8310179. Acetohydroxy acid synthase and threonine deaminase activities, and the biosynthesis of isoleucine-leucine-valine in *Streptococcus bovis*. Basso A L; Ricca E; Caruso C; Ferrara L; De Felice M. (Istituto Adattamento Bovini e Bufali Ambiente Mezzogiorno, C.N.R., Naples, Italy.) Research in microbiology, (1993 Sep) Vol. 144, No. 7, pp. 539-45. Journal code: 8907468. ISSN: 0923-2508. Pub. country: France. Language: English.

- AB Acetohydroxy acid synthase (AHAS) and threonine deaminase (TD) activities were found in *Streptococcus bovis* and shown to be involved in the biosynthesis of the branched chain amino acids isoleucine, leucine and valine. Apparent lack of repression of AHAS synthesis by the end-products and reduced sensitivity of *S. bovis* growth to analogues of the branched chain amino acids suggested that secretion of isoleucine, leucine and valine in the growth medium may be a consequence of the regulatory features of AHAS. A glycyl-leucine-resistant mutant with reduced TD activity secreted a reduced amount of isoleucine and an increased amount of valine, which might be a result of the reduced rate of synthesis of the isoleucine precursor alpha-ketobutyrate and of a consequent preferential carbon flow through the valine branch of the pathway.

L8 ANSWER 12 OF 18 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 8
1984:277613 Document No.: PREV198478014093; BA78:14093. INFLUENCE OF CULTURE REDOX POTENTIAL ON THE GROWTH AND METABOLISM OF THE RUMEN BACTERIA *SELENOMONAS-RUMINANTIUM BACTEROIDES-AMYLOPHILUS BACTEROIDES-SUCCINOGENES* AND *STREPTOCOCCUS-BOVIS* IN BATCH CULTURE. MAROUNEK M [Reprint author]; WALLACE R J. INST ANIM PHYSIOL AND GENETICS, UHRINEVES, PRAGUE, CZECH CS 251-61. Journal of General Microbiology, (1984) Vol. 130, No. 2, pp. 223-230.
CODEN: JGMIAN. ISSN: 0022-1287. Language: ENGLISH.

- AB One facultatively and 3 strictly anaerobic rumen bacteria were grown in pH-controlled anaerobic batch cultures in which the Eh (redox potential)

of the medium was regulated by the addition of titanium (III) citrate solution at values < -50 mV and potassium ferricyanide > -50 mV. Growth occurred over a wide range of Eh, with the maximum limit being +360, +250, +175 and +414 mV for *S. ruminantium*, *B. amylophilus*, *B. succinogenes* and the aerotolerant *S. bovis*, respectively. Changes in Eh had little influence on the growth yield or ratios of fermentation end-products in these bacteria over a wide range, although the specific growth rate of all species tended to decline at Eh values > 0 mV. Abnormal, elongated forms of *S. ruminantium* and *B. succinogenes* predominated at high Eh. Evidently O₂, and not a high Eh, is the toxic factor in oxidized anaerobic growth medium and it would not be necessary to regulate Eh when the growth and metabolism of these bacteria is under study, provided that O₂-free conditions are maintained.

L8 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

1985:130611 Document No. 102:130611 Study of the ability of strains of several species of lactic acid bacteria to accumulate free amino acids. Ioanisyian, T. A.; Sarkisyan, V. K.; Kharatyan, V. G. (USSR). Trudy Erevanskogo Zooveterinarnogo Instituta, 56, 30-3 (Russian) 1984. CODEN: TEZVAJ. ISSN: 0371-6562.

AB *Lactobacillus* And *Streptococcus* strains were able to accumulate in a growth medium 15.05 and 1.75 mg% free amino acids, resp. With *L. casei*, accumulation of free amino acids was 17.63 mg%. High levels of proline [147-85-3] (31.25% of total free amino acids) were found in the medium with *S. bovis*. Intrastrain differences in free amino acid formation were higher than intraspecies differences (standard deviation values reached 300-400%). Thus, the individual properties of strains should be considered in selecting lactic acid bacteria for use as bacterial starter for cheese manufacture

L8 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

1981:28871 Document No. 94:28871 Pigment production in chemostat cultures of *Streptococcus bovis*. II. Effect of carbon dioxide and pH on pigment and glucose end-products. Schein, Catherine H.; Fiechter, Armin (Swiss Fed. Inst. Technol., ETH Hoenggerberg, Zurich, CH-8093, Switz.). European Journal of Applied Microbiology and Biotechnology, 10(4), 341-8 (English) 1980. CODEN: EJABDD. ISSN: 0171-1741.

AB Seven of 8 type strains of *S. bovis*, including all 6 rumen isolates tested, produced pigment on agar media if the anaerobic atmospheric was supplemented with CO₂. Tween 80 or NaHCO₃ added to the growth medium could not substitute for gaseous CO₂. When one of the best pigment-forming strains, *S. bovis* 2B, was grown in a glucose-limited chemostat at constant dilution rate (D), decreasing the concentration of the

gas overlay resulted in pigment washout and increased lactate and cell mass. Changing pH at a constant D altered the pigment production and glucose end products of the culture.

L8 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

1978:437535 Document No. 89:37535 The effect of pH and potassium phosphate buffer on the toxicity of cadmium for bacteria. Korkeala, H.; Pekkanen, T. J. (Dep. Food Hyg., Coll. Vet. Med., Helsinki, Finland). Acta Veterinaria Scandinavica, 19(1), 93-101 (English) 1978. CODEN: AVSCA7. ISSN: 0044-605X.

AB An increase in the pH of plate count agar led to increased toxicity of Cd for *Micrococcus luteus*, *Staphylococcus aureus*, *Clostridium perfringens*, *Escherichia coli*, and *Pseudomonas aeruginosa*. The effect of the pH on toxicity was not clearly observed with *Streptococcus bovis* and was absent with *Bacillus subtilis*. When K phosphate buffer was added to the growth medium, the Cd toxicity for *M. luteus* and *B. subtilis* was enhanced. The toxicity of Cd for *S. bovis* decreased when K phosphate buffer was added to the medium. When the pH increased at differing phosphate concns., the sensitivity of *M. luteus* to Cd decreased. The effect of pH on Cd toxicity for bacteria is apparently due to a continuously increasing neg. charge towards an alkaline value by most bacteria

which increases the affinity of cations towards the cell wall.

L8 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
1973:69104 Document No. 78:69104 Pectinolytic activity of rumen streptococci. Zirolecki, Aleksander; Tomerska, Hanna; Wojciechowicz, Maria (Inst. Anim. Physiol. Nutr., Pol. Acad. Sci., Jablonna/Warsaw, Pol.). Acta Microbiologica Polonica, Series A: Microbiologia Generalis, 4(4), 183-8 (English) 1972. CODEN: AMIGB9. ISSN: 0567-7815.

AB Fourteen strains of sheep rumen streptococci were isolated and identified as Streptococcus bovis. Pectinolytic activity did not depend on the presence of pectin (I) in the growth medium, but was increased by it. I was degraded to unsatd. lower oligogalacturonides which were not further utilized by the organisms. None of the strains utilized galacturonic acid. The streptococci utilized only the sugars accompanying I and released during its degradation

L8 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
1972:445435 Document No. 77:45435 Buffer capacity of nutrient media in relation to that of rumen fluid. Stewart, C. S. (Dep. Microbiol., Rowett Res. Inst., Aberdeen, UK). Biochemical Journal, 127(3), 68P (English) 1972. CODEN: BIJOAK. ISSN: 0264-6021.

AB An increased growth rate and .apprx.30% gain in dry weight of the rumen bacteria Streptococcus bovis, Lactobacillus species 17, and Bacteroides ruminicola were obtained when grown in nutrient media buffered with phosphate or HCO₃⁻ to the same extent as rumen fluid.

L8 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
1964:470848 Document No. 61:70848 Original Reference No. 61:12356c-e Amino group formation and glutamate synthesis in Streptococcus boris. Burchall, J. J.; Niederman, R. A.; Wolin, M. J. (Univ. of Illinois, Urbana). Journal of Bacteriology, 88(4), 1038-44 (Unavailable) 1964. CODEN: JOBAAY. ISSN: 0021-9193.

AB Exts. of S. bovis grown on NH₄⁺ as a N source contain a nicotinamide adenine dinucleotide phosphate (NADP)-linked glutamic dehydrogenase and are devoid of alanine dehydrogenase, other amino acid dehydrogenases, and aspartase. A potential source of reduced NADP for glutamate synthesis is a NADP and NAD-linked glyceraldehyde-3-phosphate dehydrogenase present in the exts. Expts. with 14C-labeled glucose and NaHCO₃ indicate that the glutamate C skeleton is synthesized by a tricarboxylic acid pathway. The synthesis of the C skeleton of glutamate is repressed when glutamate or casein hydrolyzate supplement the NH₄⁺-containing growth medium. Repression of glutamic dehydrogenase and a NAD-linked isocitric dehydrogenase occurs only when complex N sources, but not when free amino acids, are added to the growth medium.

=> s lactobacillus spp

L9 2589 LACTOBACILLUS SPP

=> s l9 and adherins

L10 0 L9 AND ADHERINS

=> s l9 and adhesion

L11 70 L9 AND ADHESION

=> s l11 and growth medium

L12 0 L11 AND GROWTH MEDIUM

=> s l11 and antibod?

L13 14 L11 AND ANTIBOD?

=> dup remove l13

PROCESSING COMPLETED FOR L13

L14 4 DUP REMOVE L13 (10 DUPLICATES REMOVED)

=> d 114 1-4 cbib abs

- L14 ANSWER 1 OF 4 MEDLINE on STN DUPLICATE 1
2002651095. PubMed ID: 12381460. Adjuvant properties and colonization potential of adhering and non-adhering *Lactobacillus* spp following oral administration to mice. Plant Laura J; Conway Patricia L. (School of Microbiology and Immunology, The University of New South Wales, UNSW SYDNEY, 2052, Sydney, NSW, Australia.) FEMS immunology and medical microbiology, (2002 Oct 11) Vol. 34, No. 2, pp. 105-11. Journal code: 9315554. ISSN: 0928-8244. Pub. country: Netherlands. Language: English.
- AB This study aimed to determine whether adhesive strains of *Lactobacillus* possessed an increased ability to colonize the gastrointestinal tract and to examine the adjuvant capacities of these strains for the 50000 molecular-mass fragment C of tetanus toxin (TTFC) following oral administration. The three strains used in this study showed different patterns of adhesion to tissue from all regions of the gastrointestinal tract, with two strains adhering in high numbers and one strain showing negligible association with all tissue types. The colonization patterns in the gastrointestinal tract of C57BL/6 mice following oro-gastric dosing was also monitored, and it was found that adhesive *Lactobacillus* strains could be detected for at least 24 h, in association with either fecal material and/or with gastrointestinal tissue or contents. In addition, mice were given an oro-gastric dose of the lactobacilli (5 x 10⁸) colony forming units) with TTFC (10 and 50 micro g), and the serum-specific IgM and IgG antibody responses monitored in serum. The adhesive strains, which persisted within the gastrointestinal tract for at least 24 h, showed enhanced antigen-specific serum IgG and IgM antibody responses in comparison to a non-adhesive strain that failed to be detected in the gastrointestinal tract. Adhesion to the gastrointestinal tract is a factor affecting the capacity of lactobacilli to persist within the gastrointestinal tract and to act as an adjuvant for orally administered antigen.

- L14 ANSWER 2 OF 4 MEDLINE on STN DUPLICATE 2
2000401518. PubMed ID: 10856380. Adherence of *Lactobacillus* to intestinal 407 cells in culture correlates with fibronectin binding. Kapczynski D R; Meinersmann R J; Lee M D. (Southeast Poultry Research, USDA/ARS, Athens, GA, USA.) Current microbiology, (2000 Aug) Vol. 41, No. 2, pp. 136-41. Journal code: 7808448. ISSN: 0343-8651. Pub. country: United States. Language: English.
- AB *Lactobacilli* are members of the normal mucosal microflora of most animals. Many isolates of *Lactobacillus* spp. are adherent to epithelial cells. In this study, using *Lactobacillus acidophilus* and *L. agilis*, we detected adherence in a pattern that suggested that the bacteria were binding to extracellular matrix proteins. Fluorescent microscopy, by using anti-fibronectin antibody, demonstrated that the isolates localize in those areas where fibronectin was detected. In addition, fibronectin pretreatment of the bacterial cells decreased adherence to Intestinal 407 epithelial cell monolayers. Cellular binding to fibronectin was detected by enzyme-linked immunosorbent assay and affinity binding to radio-labeled fibronectin. Fibronectin may be one of the eukaryotic receptors mediating attachment of *Lactobacillus* to mucosal surfaces.

- L14 ANSWER 3 OF 4 MEDLINE on STN
2001416473. PubMed ID: 11464916. Lactic acid bacteria as live vaccines. Mercenier A; Muller-Alouf H; Grangette C. (Department of Microbiology of Ecosystems, Institut Pasteur de Lille, France.) Current issues in molecular biology, (2000 Jan) Vol. 2, No. 1, pp. 17-25. Ref: 49. Journal code: 100931761. ISSN: 1467-3037. Pub. country: England: United Kingdom. Language: English.
- AB Mucosal routes for vaccine delivery offer several advantages over systemic inoculation from both immunological and practical points of view. The development of efficient mucosal vaccines therefore represents a top

priority in modern vaccinology. One way to deliver protective antigens at the mucosal surfaces is to use live bacterial vectors. Until recently most of these were derived from attenuated pathogenic microorganisms. As an alternative to this strategy, non-pathogenic food grade bacteria such as lactic acid bacteria (LAB) are being tested for their efficacy as live antigen carriers. The LABVAC european research network is presently comparing the vaccine potential of *Lactococcus lactis*, *Streptococcus gordonii* and *Lactobacillus* spp. To date, it has been shown that systemic and mucosal antigen-specific immune responses can be elicited in mice through the nasal route using the three LAB systems under study. Data on successful oral and vaginal immunisations are also accumulating for *L. lactis* and *S. gordonii*, respectively. Moreover, the immune responses can be potentiated by co-expression of interleukins. Future areas of research include improvement of local immunisation efficiency, analysis of in vivo antigen production, unravelling of the *Lactobacillus* colonisation mechanisms and construction of biologically contained strains.

L14 ANSWER 4 OF 4 MEDLINE on STN DUPLICATE 3

93175875. PubMed ID: 8439162. Inhibition of adhesion of *Escherichia coli* K88 to piglet ileal mucus by *Lactobacillus* spp. Blomberg L; Henriksson A; Conway P L. (Department of General and Marine Microbiology, University of Goteborg, Sweden.) Applied and environmental microbiology, (1993 Jan) Vol. 59, No. 1, pp. 34-9. Journal code: 7605801. ISSN: 0099-2240. Pub. country: United States. Language: English.

AB Enteropathogenic *Escherichia coli* K88 colonizing the piglet ileum adhere to the mucosa by K88 fimbrial appendages. A recent study in our laboratory has implicated indigenous lactobacilli in the suppression of the colonization potential of enteropathogenic *E. coli* as measured by adhesion to ileal mucus. The aim of this study was to investigate the effect of *Lactobacillus* spp. of porcine origin on the adhesion of K88 fimbriae of *E. coli*. With an in vitro assay, the adhesion of *E. coli* K88ab strain G1108E and *E. coli* K88ac strain 1107 to 35-day-old piglet ileal mucus was studied in the presence of spent culture fluid of *Lactobacillus* spp. Detailed studies focused specifically on culture fluid of *Lactobacillus fermentum* 104R. Subsequently, the ileal mucus was exposed to the retentate of the spent culture fluid after dialysis and fractionation. Adhesion was confirmed to be attributable to K88 fimbriae when K88-specific monoclonal antibodies and isogenic mutants of *E. coli* K-12 with and without the plasmid containing the K88 gene were used. The active component was characterized by pretreatment of dialysis retentate with heat, periodate, pronase, and centrifugation, as well as by growth of the lactobacillus in various media and by assays at both 0 and 37 degrees C. All three lactobacilli of porcine origin reduced adhesion of *E. coli* K88 by approximately 50%. Inhibition occurred when mucus was pretreated with either spent culture dialysis retentate or the void volume (fraction of > 250,000 molecular weight) after gel filtration. The activity of the dialysis retentate was sensitive to pronase, but there was still activity at 0 degrees C. (ABSTRACT TRUNCATED AT 250 WORDS)

=> d his

(FILE 'HOME' ENTERED AT 13:01:19 ON 24 MAR 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 13:01:34 ON 24 MAR 2007

L1 1 S ACIDOSIS BACTERIA
L2 4259 S STREPTOCOCCUS BOVIS
L3 0 S L2 AND TRYPTASE SOY BROTH
L4 43 S L2 AND GROWTH MEDIUM
L5 0 S L4 AND ADHERINS

L6 0 S L4 AND ADHESION MOLECULE
 L7 0 S L4 AND TRYPTASE SOY BROTH
 L8 18 DUP REMOVE L4 (25 DUPLICATES REMOVED)
 L9 2589 S LACTOBACILLUS SPP
 L10 0 S L9 AND ADHERINS
 L11 70 S L9 AND ADHESION
 L12 0 S L11 AND GROWTH MEDIUM
 L13 14 S L11 AND ANTIBOD?
 L14 4 DUP REMOVE L13 (10 DUPLICATES REMOVED)

=> s l2 and adhesion

L15 32 L2 AND ADHESION

=> s l15 and antibod?

L16 4 L15 AND ANTIBOD?

=> dup remove l16

PROCESSING COMPLETED FOR L16

L17 4 DUP REMOVE L16 (0 DUPLICATES REMOVED)

=> d l17 1-4 cbib abs

L17 ANSWER 1 OF 4 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

2006463720 EMBASE Profiling the humoral immune response in colon cancer patients: Diagnostic antigens from Streptococcus bovis
 . Tjalsma H.; Scholler-Guinard M.; Lasonder E.; Ruers T.J.; Willems H.L.; Swinkels D.W.. H. Tjalsma, Department of Clinical Chemistry/441, Radboud University Nijmegen-Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, Netherlands. h.tjalsma@akc.umcn.nl. International Journal of Cancer Vol. 119, No. 9, pp. 2127-2135 1 Nov 2006.
 Refs: 31.

ISSN: 0020-7136. E-ISSN: 1097-0215. CODEN: IJCNW.

Pub. Country: United States. Language: English. Summary Language: English.

Entered STN: 20061010. Last Updated on STN: 20061010

AB The human bowel contains a large and dynamic bacterial population that is not only essential for intestinal health, but also critical for the development of diseases such as cancer. In this respect, the Gram-positive bacterium Streptococcus bovis has been associated with colon cancer for many years. To investigate the clinical importance of this association, an immunocapture mass spectrometry assay was developed that can generate infection-related protein profiles. The composition of these profiles is governed by the capture of specific antigens by serum antibodies from colon cancer patients. This assay showed that S. bovis antigen profiles could distinguish 11 out of 12 colon cancer patients from 8 control subjects, whereas antigen profiles derived from the gut bacterium Escherichia coli were not diagnostic for colon cancer. Moreover, S. bovis antigen profiles were also detected in polyp patients, indicating that infection with this bacterium does occur early during carcinogenesis. Highly accurate tandem mass spectrometry was used to identify one of the diagnostic antigens as a surface-exposed heparin-binding protein, which might be involved in attachment of S. bovis to tumor cells. Together, these findings corroborate the hypothesis that colonic lesions provide a specific niche for S. bovis, resulting in tumor-associated "silent" infections. These infections, however, only become apparent in colon cancer patients with a compromised immune system (bacteremia) or coincidental cardiac valve lesions (endocarditis). This makes profiling of the humoral immune response against "silent" S. bovis infections a promising diagnostic tool for the early detection of human colon cancer, which is crucial for the effective treatment of this disease. .COPYRGT. 2006 Wiley-Liss, Inc.

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

2004:333891 Document No. 140:351652 Anal. chip comprising evanescent field measurement platform and microarray for detection of 16S-rRNA from clin.

relevant bacteria in liquid samples. Schrenzel, Jacques; Francois, Patrice; Charbonnier, Yvan; Jacquet, Jean Gabriel; Uttinger, Dominic; Kresbach, Gerhard M.; Abel, Andreas; Ehrat, Markus (Hopitaux Universitaires De Geneve, Switz.). PCT Int. Appl. WO 2004033720 A2 20040422, 82 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-EP10626 20030924. PRIORITY: EP 2002-22631 20021009.

AB The invention is related to an anal. chip for the simultaneous determination of one or more different bacteria in a liquid sample comprising - an evanescent field measurement platform, e.g. an optical waveguide, as a solid carrier and a plurality of immobilized specific recognition elements forming an array for the detection of bacterial 16S-rRNA without amplification of the polynucleotide sequences contained in the sample. The invention is also related to an anal. method based on the use of said anal. chip to detect clin. relevant bacteria in biol. samples. Methods for immobilization of recognition elements (such as polynucleotides, peptides, antigens, etc.) on the chip are disclosed. The compns. of the layers of the optical waveguide are also disclosed.

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
2004:182241 Document No. 140:198089 Immunogen adherence inhibitor directed to lactic acid producing organisms and method of making and using it. Nash, Peter; Mitteness, Bradley M. (USA). U.S. Pat. Appl. Publ. US 2004043020 A1 20040304, 16 pp., Cont.-in-part of U.S. Ser. No. 38,260. (English). CODEN: USXXCO. APPLICATION: US 2003-658491 20030908. PRIORITY: US 1999-143985P 19990715; US 2000-201268P 20000502; US 2000-616843 20000714; US 2002-38260 20020107.

AB A microbial adherence inhibitor specific to lactic acid producing microorganisms, in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tracts of host food animals. The inhibitor is made by inoculating female birds with the immunogen, allowing time for an immune response in the female bird and then harvesting the eggs that contain antibodies to the immunogen. The egg contents can be dried or used as a liquid and added to the feed or water for the host animals. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody is used to promote the growth of food animals by improving feed conversion rates by decreasing the lactic acid production caused by the presence of certain colony-forming organisms in the animals, and to substantially reduce or eliminate the incidence of species that have been linked to very high production of lactic acid which can result in reduced performance and in acute situations, dangerously low rumen pH levels. When high levels of lactic acid are present in the rumen, rumen ulcers can form. When rumen ulcers are present other bacteria such as *Fusobacterium necrophorum* can escape the rumen and cause liver abscesses or laminitis, which further reduce feed conversion efficiency. Colony forming immunogens such as *Streptococcus bovis* (a major lactic acid producer) and *Fusobacterium necrophorum* can both be targeted by antibodies to enhance feed efficiency.

L17 ANSWER 4 OF 4 MEDLINE on STN
93316307. PubMed ID: 8392108. Adherence of glucan-positive and glucan-negative strains of *Streptococcus bovis* to human epithelial cells. Von Hunolstein C; Ricci M L; Orefici G. (Laboratorio di Batteriologia e Micologia Medica, Istituto Superiore di Sanita, Rome, Italy.) Journal of medical microbiology, (1993 Jul) Vol. 39, No. 1, pp. 53-7. Journal code: 0224131. ISSN: 0022-2615. Pub.

country: ENGLAND: United Kingdom. Language: English.

AB Adherence to buccal epithelial cells (BEC) and the role played in the binding by lipoteichoic acid (LTA) and other superficial components have been studied in reference and clinical strains of *Streptococcus bovis* either glucan-positive biotype I or glucan-negative biotype II. To avoid the synthesis of glucan by biotype I strains, adherence was studied in bacteria grown in Todd-Hewitt broth, a sucrose deficient medium. Both biotypes were shown to bind to BEC and clinical isolates, irrespective of biotype attached to the same degree but in greater numbers than reference strains. Inhibition studies suggest that at least two mechanisms, --LTA and protein-mediated--are responsible for the adherence of both glucan-positive and negative strains of *S. bovis*. Moreover, in glucan-positive strains capsular polysaccharides may be also involved.

=> s IgY

L18 2386 IGY

=> s l18 and streptococcus bovis

L19 0 L18 AND STREPTOCOCCUS BOVIS

=> s l18 and lactobacillus spp

L20 0 L18 AND LACTOBACILLUS SPP

=> s l18 and streptococcus

L21 100 L18 AND STREPTOCOCCUS

=> s l21 and bovis

L22 3 L21 AND BOVIS

=> dup remove l22

PROCESSING COMPLETED FOR L22

L23 3 DUP REMOVE L22 (0 DUPLICATES REMOVED)

=> d l23 1-3 cbib abs

L23 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

2003:737787 Document No. 139:244716 Multifunctional immune complexes for microbial phagocytosis. Pitkovski, Jacob; Morag, Ely; Pinchasov, Yosef (Yamit Biotechnologies Ltd., Israel). PCT Int. Appl. WO 2003076471 A2 20030918, 91 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-IL196 20030310. PRIORITY: IL 2002-148598 20020310.

AB The authors disclose multi-functional targeting complexes for inducing phagocytosis of pathogenic agents. The complexes of the invention comprises at least one target recognition component comprising a mol. that specifically binds to the desired target agent, an immuno-active component comprising an immuno-stimulatory agent; and optionally, a connecting component that assoc. the targeting component and the immuno-active component. In one example, the targeting component is biotinylated IgY, the immuno-active component is anti-avidin IgG, and the connecting component is avidin-conjugated polystyrene microbeads. The complex of the invention provides an effective therapeutic prevention and treatment of various pathogenic disorders, such as mastitis in cows and furunculosis in fish. The invention further relates to comps. comprising the targeting complex, methods of treatment and uses thereof.

L23 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

2004:963810 Document No. 142:239111 Method for the production of an egg

containing anti-Edwardsiella tarda IgY, anti-Streptococcus iniae IgY and Mycobacterium bovis IgY simultaneously, egg produced thereby, and fish feed containing. Baek, Ban Seok; Han, Chan Gyu; Huh, Gang Jun; Kim, Yeong Bung; Ko, Seong Chan; Lee, Nam Hyeong; Noh, Jeong Hae; Shin, Tae Beom; Son, Dong Hwa; Sung, Gi Seung (Korea Food Development Institute, S. Korea). Repub. Korean Kongkae Taeho Kongbo KR 2003000261 A 20030106, No pp. given (Korean). CODEN: KRXXA7. APPLICATION: KR 2001-35945 20010622.

AB A Method for the production of an egg containing anti-Edwardsiella tarda IgY, anti-Streptococcus iniae IgY and Mycobacterium bovis IgY simultaneously, an egg produced thereby and a fish feed containing specific IgY thereof are provided. The produced egg and fish feed have excellent prevention effect on a flatfish disease. An emulsion containing Edwardsiella tarda IgY, anti-Streptococcus iniae IgY, Mycobacterium bovis IgY and aluminum oxide in ratio of 3.0:3.0:1.0:3.0 is inoculated into a chicken in the amount of 1.0 mL one time, and then, from a 2nd time, the above emulsion and an adjuvant (ISA25) are inoculated together there into in the amount of 1.0 mL at intervals of 2 wk to produce an egg containing specific IgY. Egg yolk is then put up in a vessel, stirred in the equal amount of alkali ion water (pH 10.0), left alone for a specified period of time and then the supernatant is ultra-filtered and freeze-dried after removing a fat layer floated on the upper layer to produce soluble IgY powder.

L23 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
1997:49220 Document No. 126:130593 Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants. Coleman, Marilyn A. (Ovimmune, Inc., USA). U.S. US 5585098 A 19961217, 6 pp., Cont. of U.S. Ser. No. 156,540, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1995-369310 19950106. PRIORITY: US 1993-156540 19931123.

AB A method for lowering somatic cell count in the milk of a lactating ruminant is disclosed. IgY antibodies are first obtained from the egg of a hen which has been actively immunized against one or more mastitis-causing pathogenic organisms by injection with an immunogen containing immunogenic determinants specific to elicit such antibodies. The immunogenic determinant may comprise only a specific portion of the pathogenic organism, e.g., the fimbria of a ciliated bacterium. The IgY antibodies are then administered orally to a ruminant in which it is desired to lower milk somatic cell count. Antibody administration may occur during a ruminant's dry period as well as during lactation. In a preferred embodiment, the antigen used in immunization of the hen comprises one or more of Staphylococcus aureus and Streptococcus agalactiae. The method of this invention has been shown to be efficacious in lowering somatic cell count in dairy cattle.

=> sl18 and lactobacillus

SL18 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> d l18 and lactobacillus

'AND' IS NOT A VALID FORMAT

'LACTOBACILLUS' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):d his

'D' IS NOT A VALID FORMAT

'HIS' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid

in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):abs

L18 ANSWER 1 OF 2386 MEDLINE on STN

AB Incomplete Freund's adjuvant (IFA) is used as standard adjuvant for the production of specific antibodies. In this study, we evaluated the ability of supplementation of IFA with 1 α ,25-dihydroxyvitamin D(3) [1 α ,25(OH)(2)D(3)] or C-phosphate-guanosine-oligodeoxynucleotide (CpG-ODN) to enhance the quantity of specific IgY found in the eggs of hyperimmunized laying hens. In this comparative study, the fimbrial adhesin F4 of porcine enterotoxigenic Escherichia coli was used as prototype immunogen. Hens of 3 groups received by i.m. injection 20 μ g of purified F4 adhesin emulsified with 1 of the following adjuvants: 0.5 mL of IFA alone (F4-IFA group), 0.5 mL of IFA supplemented with 285.6 ng of 1 α ,25(OH)(2)D(3) (F4-IFA-D(3) group), or 0.5 mL of IFA supplemented with 10 μ g of CpG-ODN (F4-IFA-CpG group). Hens of 2 control groups received PBS or purified F4 alone. Immunization was repeated after 2 and 5 or 7 wk. Eggs were collected at 3- to 4-d intervals from preimmunization to d 79, and whole eggs were tested to measure the quantity of anti-F4 IgY by a standardized indirect ELISA. The quantity of specific anti-F4 IgY present in eggs from immunized hens of the F4-IFA group increased from d 13 to 79, corresponding to the end of the experiment. The values for this group at each time were considered as 100%. Results obtained for the other adjuvants were expressed in relation to this reference method. Supplementation of IFA with 1 α ,25(OH)(2)D(3) did not result in any enhancement of the quantity of anti-F4 IgY present in the eggs. On the other hand, supplementation of IFA with CpG-ODN resulted in an enhancement of yield up to 942% of the F4-specific antibody response. Moreover, the use of CpG-ODN is a cost-effective and ethical refinement for the production of specific antibodies, permitting a reduction in the number of immunizations needed. In conclusion, this study provides strong evidence for the use of IFA supplemented with CpG-ODN rather than IFA alone for the production of high levels of specific antibody in laying hens.

=> s l18 and lactobacillus

L24 15 L18 AND LACTOBACILLUS

=> dup remove l24

PROCESSING COMPLETED FOR L24

L25 11 DUP REMOVE L24 (4 DUPLICATES REMOVED)

=> d l25 1-11 cbib abs

L25 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

2007:234267 A study of the effects of IgY and Lactobacillus on the prevention and treatment of vaginal infection due to Candida albicans. Zhang, Wenping; Ma, Lianlan; Xie, Shuixiang; Fu, Yingyuan (Department of Pathogenic Biology, Gannan Medical College, Ganzhou, 341000, Peop. Rep. China). Shaanxi Yixue Zazhi, 35(2), 142-145 (Chinese) 2006. CODEN: SYZAEI. ISSN: 1000-7377. Publisher: Shaanxi Yixue Zazhi Bianjibu.

AB The objective is to observe the bio-activity of anti-Candida albicans IgY and Lactobacillus in vivo and in vitro and to study the possibility of combined application of them. The human vaginal epithelium cells were isolated and adherence inhibition experiment was performed after pretreating C.albicans and buccal Epithelium cells with anti-C.albicans IgY and Lactobacillus. After the mouse model of vaginitis infected with C.albicans, therapeutic effects of anti-C.albicans IgY and Lactobacillus administered vaginally were observed. Anti-C.albicans IgY and Lactobacillus can inhibit adherence of Candida albicans to vaginal

epithelium cells and reduce the vaginal C.albicans colonization as well as alleviate typical signs of mouse with C.albicans colonization. Anti-C.albicans IgY is of good biol. effect against Candida albicans in vivo and intro, and is better than that of Lactobacillus used independently, suggesting that the combined use of IgY and Lactobacillus can result in ideal effect.

L25 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

2005:58248 Document No. 142:154246 Pharmaceutical composition comprising egg yolk antibodies and probiotics for combination therapy of gastroenteric diseases caused by microorganisms. Alfa, Michelle (Avitek Pharma Inc., Can.). PCT Int. Appl. WO 2005005481 A2 20050120, 30 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-CA1005 20040712. PRIORITY: US 2003-485722P 20030710.

AB The manufacture of a pharmaceutical composition comprising egg yolk antibodies and

at least one probiotic and the use thereof to treat diseases caused by enteric pathogens is described. In one embodiment the technol. is a multi-faceted therapeutic treatment to prevent diarrheal disease due to Clostridium difficile. The combination therapy comprises targeted delivery of avian IgY antibodies that neutralize the toxins produced by C. difficile (toxin A and toxin B) and nutraceuticals that restore normal bowel ecosystem balance and prevent the overgrowth of C. difficile.

L25 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

2005:1230992 Document No. 144:50039 Manufacture of IgY products for treating oral and upper respiratory infections. Ye, Shaojun; Zhou, Feng; Chen, Rulei; Yin, Juan (Peop. Rep. China). Faming Zhuanli Shenqing Gongkai Shuomingshu CN 1569229 A 20050126, 12 pp. (Chinese). CODEN: CNXXEV. APPLICATION: CN 2003-149558 20030717.

AB This invention relates to the manufacture of various chicken yolk Ig IgY products with specific anti-infective effects, the formulations of products containing IgY, and their specific applications. The IgY products can be used for treating dental caries, periodontal diseases, oral mucosa diseases, influenza, and laryngopharyngitis.

L25 ANSWER 4 OF 11 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN

2005:302112 The Genuine Article (R) Number: 905AO. Protective effect of microencapsulation consisting of multiple emulsification and heat gelation processes on immunoglobulin in yolk. Cho Y H; Lee J J; Park I B; Huh C S; Baek Y J; Park J (Reprint). Yonsei Univ, Dept Biotechnol, Seoul 120749, South Korea (Reprint); Korea Yakult Co Ltd, R&D Ctr, Yongin, South Korea. foodpro@yonsei.ac.kr. JOURNAL OF FOOD SCIENCE (MAR 2005) Vol. 70, No. 2, pp. E148-E151. ISSN: 0022-1147. Publisher: INST FOOD TECHNOLOGISTS, 525 WEST VAN BUREN, STE 1000, CHICAGO, IL 60607-3814 USA. Language: English. *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

AB Two different emulsification methods involving multiple emulsification and heat gelation were used for preparation of whey protein-based microcapsules containing immunoglobulin in yolk (IgY). The residual activity of IgY during the emulsion preparation and the effects of microencapsulation on IgY stability under harsh conditions were investigated. The residual activity of IgY in an emulsion prepared with a membrane emulsifier was higher than for an emulsion using a homogenizer. Microencapsulated IgY showed remarkable stability against both pepsin and acid. Both microencapsulated

IgY and nonencapsulated IgY were relatively stable in bile and artificial intestinal juice. Microencapsulated IgY retained 74% of initial activity during heat treatment. There were no significant differences in the residual activities of microencapsulated IgY under storage temperatures of 4, 25, and 37 degrees C.

- L25 ANSWER 5 OF 11 MEDLINE on STN DUPLICATE 1
2004572825. PubMed ID: 15545368. Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on *Helicobacter pylori* in humans. Horie K; Horie N; Abdou A M; Yang J-O; Yun S-S; Chun H-N; Park C-K; Kim M; Hatta H. (Research Department, Pharma Foods International Company, Ltd., Kyoto 601-8357, Japan.) Journal of dairy science, (2004 Dec) Vol. 87, No. 12, pp. 4073-9. Journal code: 2985126R. ISSN: 0022-0302. Pub. country: United States. Language: English.
- AB *Helicobacter pylori* is a human pathogen that infects over 50% of the population worldwide. It is the most important etiologic agent of gastroduodenal ulcers and malignancies. *Helicobacter pylori* urease enzyme is considered the main factor for the organism's colonization in the gastroduodenal mucosa. Hens immunized with the purified urease produce a highly specific anti-H. *pylori* urease immunoglobulin (IgY-urease) in their egg yolks. Immunoglobulin Y-urease was stable at 60 to 65 degrees C for 30 min and at pH 4.0 for 7 h. Its activity was lost at 80 degrees C for 20 min and at pH 2 for 4 h. Specially designed functional drinking yogurt containing *Lactobacillus acidophilus* and *Bifidobacterium* spp. with 1% egg yolk IgY-urease was produced commercially. Immunoglobulin Y-urease activity showed stability in the product up to 7 d, and then decreased to 85% after 3 wk of storage. A clinical study was conducted to determine the effectiveness of IgY-urease yogurt to suppress infection in humans. Forty-two volunteers who tested positive for H. *pylori* using a ¹³C-urea breath test were recruited. A total of 450 mL of IgY-urease (test group) or IgY-urease-free yogurt (control group) was consumed in 150-mL portions 3 times daily for 4 wk. Volunteers were tested after 2 and 4 wk; urea breath test values significantly decreased in the test group compared with the control group. The results indicate that suppression of H. *pylori* infection in humans could be achieved by consumption of drinking yogurt fortified with IgY-urease.

- L25 ANSWER 6 OF 11 MEDLINE on STN
2003160635. PubMed ID: 12621086. Identification of immunodominant *Helicobacter pylori* proteins with reactivity to H. *pylori*-specific egg-yolk immunoglobulin. Shin Ji-Hyun; Nam Seung-Woo; Kim Jung-Taik; Yoon Jong-Bok; Bang Won-Gi; Roe Im-Hwan. (Research Center for Gastroenterology and Department of Gastroenterology, Dankook University College of Medicine, Cheonan, Korea.) Journal of medical microbiology, (2003 Mar) Vol. 52, No. Pt 3, pp. 217-22. Journal code: 0224131. ISSN: 0022-2615. Pub. country: England; United Kingdom. Language: English.
- AB The importance of hens eggs as a source of specific antibodies (IgY) is well recognized. The protective effect of IgY obtained from hens immunized with *Helicobacter pylori* whole-cell lysate has been reported for the control of H. *pylori* infection. However, IgY produced by whole-cell lysates presents the possibility of cross-reactivity with other bacteria, including the normal human flora, and this could decrease the efficiency of IgY. In the present study, the immunodominant proteins of H. *pylori* with reactivity to H. *pylori*-specific IgY (IgY-Hp) were identified. IgY obtained from hens immunized with various fractions of H. *pylori* proteins was isolated and purified, titres of IgY-Hp against H. *pylori* were determined and cross-reactivity between IgY-Hp and normal human bacteria was examined by Western blot analysis. Finally, immunodominant H. *pylori* proteins were identified by LC/MS analysis. IgY obtained 2 months after immunization with H. *pylori* whole-cell lysate showed the highest antibody titre. Five immunodominant proteins were identified that were strongly reactive to IgY-Hp: urease beta-subunit (62 kDa), heat-shock protein 60 (60

kDa), urease alpha-subunit (26 kDa), probable peroxiredoxin (22 kDa) and probable thiol peroxidase (18 kDa). Immunization of hens with the immunodominant proteins identified would produce a more specific IgY against *H. pylori*.

L25 ANSWER 7 OF 11 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN 2003:68564 Document No.: PREV200300068564. Food containing active strains for inhibiting infection and treating gastritis, gastric and duodenal ulcers. Heo, Cheol Seong [Inventor, Reprint Author]; Lee, Jeong Jun [Inventor]; Baek, Young Jin [Inventor]; Kim, Hyung Soo [Inventor]. Chunan, South Korea. ASSIGNEE: Korea Yakult Co. Ltd., Seoul, South Korea. Patent Info.: US 6491956 20021210. Official Gazette of the United States Patent and Trademark Office Patents, (Dec 10 2002) Vol. 1265, No. 2. <http://www.uspto.gov/web/menu/patdata.html>. e-file. ISSN: 0098-1133 (ISSN print). Language: English.

AB Live strains of *Lactobacillus acidophilus* HY2177 and *Lactobacillus casei* HY2743 maintained in nutritious foods, such as yogurt, imbue them with prophylactic and/or therapeutic properties. Such foods are beneficial in the prevention and/or treatment of gastritis, duodenal and gastric ulcers caused by infection from *Helicobacter pylori* (also referred to as *H. pylori*). The properties of these bacteria are boosted by the addition of egg yolk containing antibodies specific to *H. pylori* antigen derived from "fractionated *H. pylori*" and may be administered as active strains alone in a food supplement, or the active strains may be combined with *H. pylori*-antibodies (IgY).

L25 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN 2002:171954 Document No. 136:215882 Stabilization of immunoglobulins at a low pH for inclusion in beverages. Norman, Daniel; Johansson, Marie-louise; Akesson, Bjoern; Nyberg, Lena; Paulsson, Marie (Probi Ab, Swed.). PCT Int. Appl. WO 2002018442 A1 20020307, 25 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-SE1836 20010829. PRIORITY: SE 2000-3045 20000829.

AB The authors disclose methods for stabilizing Igs in a solution having a pH below 4. The methods include the addition of cereals, hydrolyzed cereal products, or fruit juice concs. added in an amount sufficient to prevent Ig degradation. The invention also refers to a health/sports drink comprising Igs in a solution having a pH of 2.7-3.8, which are stabilized by the addition of cereals or hydrolyzed cereal products, and which can optionally also contain a probiotic bacterium.

L25 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN 2002:236546 Food containing active strains for inhibiting infection and treating gastritis, gastric and duodenal ulcers. Heo, Cheol Seong; Lee, Jeong Jun; Baek, Young Jin; Kim, Hyung Soo (Korea Yakult Co. Ltd., S. Korea). U.S. Pat. Appl. Publ. US 20020037341 A1 20020328 (English). CODEN: USXXCO. APPLICATION: US 2001-974461 20011010. PRIORITY: US 2000-2000/498668 20000207.

AB Live strains of *Lactobacillus acidophilus* HY2177 and *Lactobacillus casei* HY2743 maintained in nutritious foods, such as yogurt, imbue them with prophylactic and/or therapeutic properties. Such foods are beneficial in the prevention and/or treatment of gastritis, duodenal and gastric ulcers caused by infection from *Helicobacter pylori* (also referred to as *H. pylori*). The properties of these bacteria are boosted by the addition of egg yolk containing antibodies specific to *H. pylori* antigen derived from "fractionated *H. pylori*" and may be administered as active strains alone in a food supplement, or the active strains may be combined with *H. pylori*-antibodies (IgY).

L25 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
2001:459863 Document No. 135:66222 Compositions for treatment of periodontal disease, and device for applying the compositions. Oka, Hironori (Japan).
Jpn. Kokai Tokkyo Koho JP 2001172186 A 20010626, 12 pp. (Japanese).
CODEN: JKXXAF. APPLICATION: JP 1999-357002 19991216.
AB The invention relates to an agent for treatment of periodontal disease containing deep sea water, super oxidized water, magnetic wave-motion water, alkali ion water, and/or antibody-containing water, suitable for apply to teeth or gingiva with a specified device. A solution containing deep sea water 1.5, egg yolk antibody powder containing IgY against actinobacillus actinomycetecomitans 0.1 g was formulated and applied to patients with periodontal disease.

L25 ANSWER 11 OF 11 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
DUPLICATE 2
1991:322937 Document No.: PREV199192033452; BA92:33452. DETECTION OF CORYNEBACTERIUM-SEPEDONICUM WITH ANTIBODIES RAISED IN CHICKEN EGG YOLKS. UNDERBERG H A [Reprint author]; SANDER E. BIOL INST, UNIV TUEBINGEN, AUF MORGENSTELLE 28, D-7400 TUEBINGEN, GERMANY. Zeitschrift fuer Pflanzenkrankheiten und Pflanzenschutz, (1991) Vol. 98, No. 2, pp. 188-196.
CODEN: ZPFPA. ISSN: 0340-8159. Language: ENGLISH.

AB The suitability of purified antibodies raised in chicken egg yolk (IgY) for the detection of Corynebacterium sepedonicum (C. s.) was compared with antibodies from rabbit (IgG) in various formats of ELISA. The DAS-ELISA employing IgY antibodies as well for coating as for the alkaline phosphatase conjugate proved to be the most sensitive assay, the detection limit being $5 + 10^5$ bacteria/ml sample buffer. When this assay was performed in potato tuber sap (1:5 diluted in sample buffer), there was no loss in sensitivity and no non-specific reactions were observed in the tuber sap. The purified IgY were assayed for cross-reactivity. There were no cross-reactions with C. flaccumfaciens, C. insidiosum, C. michiganense, C. nebrascense and Erwinia chrysanthemi and four out of six Lactobacillus-like strains. The latter were isolated because of their cross-reactivity in the fluorescent-antibody-staining assay. The high degree of specificity was effected by preadsorption of the antibody population to C. s. By this step, nonspecific antibodies are separated from C. s.-specific antibodies, which are released from the bacteria by pH shift later. When extensively compared with IgG from rabbit, the IgY type was equally suited as the IgG type antibodies. Moreover, the IgY can be obtained less cumbersome in larger quantities than IgG from serum.

=> s (nash p?/au or mITTENESS b?/au)
L26 1234 (NASH P?/AU OR MITTENESS B?/AU)

=> s 126 and microbial adherence inhibitor
L27 2 L26 AND MICROBIAL ADHERENCE INHIBITOR

=> dup remove 127
PROCESSING COMPLETED FOR L27
L28 2 DUP REMOVE L27 (0 DUPLICATES REMOVED)

=> d 128 1-2 cbib abs

L28 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
2004:182241 Document No. 140:198089 Immunogen adherence inhibitor directed to lactic acid producing organisms and method of making and using it. Nash, Peter; MITTENESS, Bradley M. (USA). U.S. Pat. Appl. Publ. US 2004043020 A1 20040304, 16 pp., Cont.-in-part of U.S. Ser. No. 38,260. (English). CODEN: USXXCO. APPLICATION: US 2003-658491 20030908. PRIORITY: US 1999-143985P 19990715; US 2000-201268P 20000502; US 2000-616843 20000714; US 2002-38260 20020107.

AB A microbial adherence inhibitor specific to lactic acid producing microorganisms, in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tracts of host food animals. The inhibitor is made by inoculating female birds with the immunogen, allowing time for an immune response in the female bird and then harvesting the eggs that contain antibodies to the immunogen. The egg contents can be dried or used as a liquid and added to the feed or water for the host animals. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody is used to promote the growth of food animals by improving feed conversion rates by decreasing the lactic acid production caused by the presence of certain colony-forming organisms in the animals, and to substantially reduce or eliminate the incidence of species that have been linked to very high production of lactic acid which can result in reduced performance and in acute situations, dangerously low rumen pH levels. When high levels of lactic acid are present in the rumen, rumen ulcers can form. When rumen ulcers are present other bacteria such as *Fusobacterium necrophorum* can escape the rumen and cause liver abscesses or laminitis, which further reduce feed conversion efficiency. Colony forming immunogens such as *Streptococcus bovis* (a major lactic acid producer) and *Fusobacterium necrophorum* can both be targeted by antibodies to enhance feed efficiency.

L28 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
2002:555957 Document No. 137:124202 Chicken egg antibodies for inhibiting adherence of colony-forming organism in rumen and intestinal tract of food animal. Nash, Peter; Rosevear, John W.; Robinson, Donald L. (USA). U.S. Pat. Appl. Publ. US 2002098181 A1 20020725, 12 pp., Division of U.S. Ser. No. 616,843. (English). CODEN: USXXCO. APPLICATION: US 2002-38260 20020107. PRIORITY: US 1999-143985P 19990715; US 2000-201268P 20000502; US 2000-616843 20000714.

AB A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tracts of host food animals. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, harvesting the eggs which contain antibodies to the immunogen, drying the egg contents and adding to the feed or water for the host animals. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody is used to promote the growth of food animals by improving feed conversion rates by decreasing the waste of dietary protein caused by the presence of certain colony-forming organisms in the animals, and to substantially reduce or eliminate the incidence of illnesses caused by the presence of certain illness-causing colony-forming immunogens, such as *Escherichia coli* O157:H7, in meat from food animals, and in other food stuffs.

=> s 126 and IgY
L29 1 L26 AND IGY

=> d 129 chib abs

L29 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
2004:681184 Document No. 141:172883 Passive immunity with avian antibodies to respiratory pathogens. Nash, Peter; Mitteness, Bradley M. (USA). U.S. Pat. Appl. Publ. US 2004161427 A1 20040819, 12 pp. (English). CODEN: USXXCO. APPLICATION: US 2004-775557 20040210. PRIORITY: US 2003-447904P 20030219.

AB The authors disclose the preparation and application of fowl egg antibodies in preventing the attachment or adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitory antibodies are made by inoculating female birds (e.g., chickens) with the immunogen,

harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air. In one example, antibodies derived from chickens were immunized with Pasteurella and Haemophilus immunogens were delivered as a top dressing to feed for swine. Compared to baseline controls, treated swine exhibited less mortality and a reduced requirement for antibiotic medication.

=> s avian antibod?

L30 182 AVIAN ANTIBOD?

=> s l30 and streptococcus

L31 1 L30 AND STREPTOCOCCUS

=> d l31 cbib abs

L31 ANSWER 1 OF 1 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN

2003:800509 The Genuine Article (R) Number: 719JL. Production of antibodies in chickens. Narat M (Reprint). Univ Ljubljana, Biotechnol Fac, Dept Anim Sci, Groblje 3, SI-1230 Domzale, Slovenia (Reprint); Univ Ljubljana, Biotechnol Fac, Dept Anim Sci, SI-1230 Domzale, Slovenia. FOOD TECHNOLOGY AND BIOTECHNOLOGY (JUL-SEP 2003) Vol. 41, No. 3, pp. 259-267. ISSN: 1330-9862. Publisher: FACULTY FOOD TECHNOLOGY BIOTECHNOLOGY, UNIV ZAGREB, KACIECEVA 23, 41000 ZAGREB, CROATIA. Language: English.
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Chickens, as a source of desired antibodies, represent an alternate animal system that offers some advantages with respect to animal care, high productivity and special suitability of avian antibodies for certain diagnostic purposes. Despite being an excellent counterpart to mammal IgG chicken IgY antibodies still represent an underused resource. This may be due to the lack of information concerning the possibility of production and application of IgY or their use is being hampered by problems with keeping the chickens and with IgY isolation. As a suggestion how to overcome IgY isolation problems a new immunoaffinity isolation method is presented here. The main purpose of the present work is to provide information on developments and possibilities in the production of chicken IgY. Polyclonal, monoclonal and recombinant forms of IgY, successfully produced so far, as well as their applications are summarised. This article should be a contribution to the efforts of the European Centre for the Validation of Alternative Methods (ECVAM), whose main goal is to promote the scientific and regulatory acceptance of alternative methods, which are of importance to the bioscience and which reduce, refine or replace the use of laboratory animals.

=> s l30 and lacobacillus

L32 0 L30 AND LACOBACILLUS

=> d his

(FILE 'HOME' ENTERED AT 13:01:19 ON 24 MAR 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 13:01:34 ON 24 MAR 2007

L1 1 S ACIDOSIS BACTERIA
L2 4259 S STREPTOCOCCUS BOVIS
L3 0 S L2 AND TRYPTASE SOY BROTH
L4 43 S L2 AND GROWTH MEDIUM
L5 0 S L4 AND ADHERINS
L6 0 S L4 AND ADHESION MOLECULE
L7 0 S L4 AND TRYPTASE SOY BROTH

L8 18 DUP REMOVE L4 (25 DUPLICATES REMOVED)
 L9 2589 S LACTOBACILLUS SPP
 L10 0 S L9 AND ADHERINS
 L11 70 S L9 AND ADHESION
 L12 0 S L11 AND GROWTH MEDIUM
 L13 14 S L11 AND ANTIBOD?
 L14 4 DUP REMOVE L13 (10 DUPLICATES REMOVED)
 L15 32 S L2 AND ADHESION
 L16 4 S L15 AND ANTIBOD?
 L17 4 DUP REMOVE L16 (0 DUPLICATES REMOVED)
 L18 2386 S IGY
 L19 0 S L18 AND STREPTOCOCCUS BOVIS
 L20 0 S L18 AND LACTOBACILLUS SPP
 L21 100 S L18 AND STREPTOCOCCUS
 L22 3 S L21 AND BOVIS
 L23 3 DUP REMOVE L22 (0 DUPLICATES REMOVED)
 L24 15 S L18 AND LACTOBACILLUS
 L25 11 DUP REMOVE L24 (4 DUPLICATES REMOVED)
 L26 1234 S (NASH P?/AU OR MITTENESS B?/AU)
 L27 2 S L26 AND MICROBIAL ADHERENCE INHIBITOR
 L28 2 DUP REMOVE L27 (0 DUPLICATES REMOVED)
 L29 1 S L26 AND IGY
 L30 182 S AVIAN ANTIBOD?
 L31 1 S L30 AND STREPTOCOCCUS
 L32 0 S L30 AND LACOBACILLUS

=> s l18 and carrier

L33 54 L18 AND CARRIER

=> s l33 and feed carrier

L34 1 L33 AND FEED CARRIER

=> d l34 chib abs

L34: ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

2003:591031 Document No. 139:132461 Inhibition of gut bacterial adherence
 and colonization by egg-derived antibodies. (Camas, Incorporated, USA).
 PCT Int. Appl. WO 2003061693 A1 20030731, 54 pp. DESIGNATED STATES: W:
 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR,
 CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
 IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
 MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
 TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW; RW: AT, BE, BF, BJ, CF,
 CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML,
 MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.
 APPLICATION: WO 2001-US49588 20011228.

AB A microbial adherence inhibitor in the form of fowl egg antibodies is
 disclosed, along with the method of making it and methods of using it.
 The inhibitor functions by substantially preventing the attachment or
 adherence of colony-forming immunogens in the rumen and intestinal tracts
 of host food animals. The inhibitor is made by inoculating female birds
 with the immunogen, harvesting the eggs which contain antibodies to the
 immunogen, drying the egg contents and adding to the feed or water for the
 host animals. Dependent upon the particular immunogen with which the
 female bird is inoculated, the egg antibody is used to promote the growth
 of food animals by improving feed conversion rates by decreasing the waste
 of dietary protein caused by the presence of certain colony-forming
 organisms in the animals, and to substantially reduce or eliminate the
 incidence of illnesses caused by the presence of certain illness-causing
 colony-forming immunogens, such as E. coli O157:H7, in meat from food
 animals, and in other food stuffs.

=> s l33 adn soybean

MISSING OPERATOR L33 ADN

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l33 and soybean
L35 1 L33 AND SOYBEAN

=> d l35 cbib abs

L35 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
2004:681184 Document No. 141:172883 Passive immunity with avian antibodies to respiratory pathogens. Nash, Peter; Mitteness, Bradley M. (USA). U.S. Pat. Appl. Publ. US 2004161427 A1 20040819, 12 pp. (English). CODEN: USXXCO. APPLICATION: US 2004-775557 20040210. PRIORITY: US 2003-447904P 20030219.

AB The authors disclose the preparation and application of fowl egg antibodies in preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitory antibodies are made by inoculating female birds (e.g., chickens) with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air. In one example, antibodies derived from chickens were immunized with Pasteurella and Haemophilus immunogens were delivered as a top dressing to feed for swine. Compared to baseline controls, treated swine exhibited less mortality and a reduced requirement for antibiotic medication.

=> s l18 and feed carrier
L36 1 L18 AND FEED CARRIER

=> d l36 cbib abs

L36 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
2003:591031 Document No. 139:132461 Inhibition of gut bacterial adherence and colonization by egg-derived antibodies. (Camas, Incorporated, USA). PCT Int. Appl. WO 2003061693 A1 20030731, 54 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US49588 20011228.

AB A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tracts of host food animals. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, drying the egg contents and adding to the feed or water for the host animals. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody is used to promote the growth of food animals by improving feed conversion rates by decreasing the waste of dietary protein caused by the presence of certain colony-forming organisms in the animals, and to substantially reduce or eliminate the incidence of illnesses caused by the presence of certain illness-causing colony-forming immunogens, such as E. coli O157:H7, in meat from food animals, and in other food stuffs.

=> s l18 and corn
L37 9 L18 AND CORN

=> dup remove 137

PROCESSING COMPLETED FOR L37

L38 6 DUP REMOVE L37 (3 DUPLICATES REMOVED)

=> d 138 1-6 cbib abs

L38 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

2003:97257 Document No. 138:142481 Enteral compositions containing phospholipids, triglycerides and cholesterol for the prevention and/or treatment of sepsis. Hageman, Robert Johan Joseph; Speelmans, Gelske; Vriesema, Adrianus Johannes Maria (Nutricia N.V., Neth.). PCT Int. Appl. WO 2003009704 A2 20030206, 22 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-NL510 20020726. PRIORITY: EP 2001-202873 20010727.

AB The present invention relates to an enteral composition containing phospholipids, triglycerides and cholesterol or precursors thereof, which can be used in the treatment of sepsis. With the composition of the invention the natural level of chylomicrons is maintained, in particular in gut associated lymphoid tissue (GALT), which ensures that most of LPS and/or LTA which are released in the body can be neutralized, substantially decreasing the risk of locally occurring high levels of LPS and/or LTA and thus sepsis.

L38 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

2004:970576 Document No. 142:218061 Antibiotic-free feed composition. Kim, Jeong U. (Dan Biotech, S. Korea). Repub. Korean Kongkae Taeho Kongbo KR 2003012563 A 20030212, No pp. given (Korean). CODEN: KRXXA7. APPLICATION: KR 2001-46638 20010801.

AB A substitute feed composition for antibiotics is provided, thereby easily increasing immunity and health of domestic animals without using antibiotics. The substitute feed composition for antibiotics comprises 0.1 to 10% of eggs containing IgY obtained from laying hens immunized by an antigen selected from the group consisting of F4:K88, F5:K99, F6:987P, F18 and F41. It further comprises 35 to 45% of corn, 20 to 30% of dried whey, 10 to 20% of soybean waste, 5 to 15% of soybean protein, 0.5 to 8% of spray-dried blood, 0.5 to 8% of fish protein powder, 1 to 5% of animal lipid, 0.5 to 5% of calcium phosphate, 0.05 to 3% of limestone, 0.05 to 1% of premix of vitamin and mineral, 0.01 to 3% of salt, 0.01 to 3% of lysine, and 0.01 to 3% of methionine.

L38 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

2001:816695 Document No. 135:354990 Simulated activity of protein A displayed by ligands attached to a cellulose bead surface for affinity purification of proteins. Stipanovic, Bozidar; Griffin, Martin; Scarpa, Ioannis (Accurate Polymers, Inc., USA). PCT Int. Appl. WO 2001083515 A2 20011108, 23 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US13970 20010430. PRIORITY: US 2000-PV200591 20000428.

AB A method and compound for the purification of proteins includes the attachment to a support matrix of a non-peptidic, small compound which simulates the affinity of protein A for Igs. Once attached on the support matrix, the

resulting monochloro-triazine derivative is reacted with an excess of an amino compound at a higher temperature to achieve high levels of substitution. The resulting support matrix with ligand is useful in the affinity sepns. of antibodies. Further, a mercapto heterocyclic system ligand may be attached to the super matrix and is useful in affinity sepns. of antibodies. Orbicell beads having a primary or secondary amino group were reacted with triepoxide and then with thioimidazol to make beads for isolating IgY from egg yolk.

L38 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

2000:181011 Document No. 132:227451 Sustained-release preparations containing emulsified compositions. Horie, Noriko; Sakaguchi, Noboru (Taiyo Kagaku Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2000080027 A 20000321, 5 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1998-264031 19980902.

AB The prepns., which show sustained-release property in stomach based on gradual destruction of the emulsion by gastric acid, contain emulsified compns., e.g. containing yolk antibodies, mammal serum antibodies, etc. IgY was dissolved in a phosphate buffer and the solution was emulsified with corn oil using condensed ricinoleic acid polyglycerin ester fatty acid esters to give a W/O emulsion. Antibody activity of the emulsion in an artificial gastric juice at 37° was decreased from 0.48 to 0.46 after 2 h, vs. from 0.50 to 0.01 after 30 min of an aqueous IgY solution as a control.

L38 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

1998:256225 Document No. 128:320910 Dentifrices and food additives showing anticaries activities, etc., containing anti-Streptococcus mutans antibodies, etc.. Sunahori, Shinichi; Okabe, Keiichiro (Advance K. K., Japan). Jpn. Kokai Tokkyo Koho JP 10108648 A 19980428 Heisei, 7 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1996-279869 19961002.

AB Dentifrices and food additives showing anticaries, anti-periodontal disease, and hair-growing effects contain ≥ 2 selected from anti-Streptococcus mutans antibodies, plant leaf polyphenols, and 5'-deoxy-5'-methylthioadenosine (vitamin L2; I), vehicles which impart thickness and are held in oral cavity, and optional vitamins, intestinal bacteria exts., Ca powders, etc. A mixture of I, SunGY SMB (IgY to anti-S.), and Sunphenone (polyphenol) significantly inhibited dental plaque formation in dogs. A freeze-dried composition containing soluble starch, Na polyacrylate, Na alginate, I, intestinal bacteria extract, freeze-dried powder of intestinal bacteria culture, vitamin mixture, Ca gluconate, Ca, green tea polyphenol, yolk anti-S. mutans antibodies, and corn starch was formulated.

L38 ANSWER 6 OF 6

MEDLINE on STN

DUPLICATE 1

86085831. PubMed ID: 2416749. Human plasma prekallikrein. Immunoaffinity purification and activation to alpha- and beta-kallikrein. Burger D; Schleuning W D; Schapira M. The Journal of biological chemistry, (1986 Jan 5) Vol. 261, No. 1, pp. 324-7. Journal code: 2985121R. ISSN: 0021-9258. Pub. country: United States. Language: English.

AB Prekallikrein was purified from human plasma with a final yield of 76% using as the principal step adsorption to immobilized chicken antikallikrein IgY. When purified prekallikrein (3.4 microM) was incubated in the presence of beta-Factor XIIa (0.068 microM) for 5 min at 37 degrees C and pH 7.5, alpha-kallikrein was obtained. Upon prolonged incubation (0.5-28 h), the Mr 52,000 heavy chain of alpha-kallikrein was progressively cleaved, resulting in the formation of beta-kallikrein. The formation of beta-kallikrein was characterized as an autolytic process because it was prevented by specific inhibitors of kallikrein, including aprotinin and antikallikrein antibody but not by corn trypsin inhibitor, an inhibitor specific for beta-Factor XIIa.

L39 0 L18 AND SOYBEAN HULLS

=> s l18 and rice hulls

L40 0 L18 AND RICE HULLS

=> s l18 and cottonseed hulls

L41 1 L18 AND COTTONSEED HULLS

=> d l41 cbib abs

L41 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

2003:591031 Document No. 139:132461 Inhibition of gut bacterial adherence and colonization by egg-derived antibodies. (Camas, Incorporated, USA). PCT Int. Appl. WO 2003061693 A1 20030731, 54 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US49588 20011228.

AB A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tracts of host food animals. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, drying the egg contents and adding to the feed or water for the host animals. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody is used to promote the growth of food animals by improving feed conversion rates by decreasing the waste of dietary protein caused by the presence of certain colony-forming organisms in the animals, and to substantially reduce or eliminate the incidence of illnesses caused by the presence of certain illness-causing colony-forming immunogens, such as E. coli O157:H7, in meat from food animals, and in other food stuffs.

=> s l18 and distilled dried grains

L42 0 L18 AND DISTILLED DRIED GRAINS

=> s l18 and beet pulp

L43 0 L18 AND BEET PULP

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

281.88

282.09

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-24.18

-24.18